Na+/H+ exchanger 3 blockade ameliorates type 2 diabetes mellitus via inhibition of sodium-glucose co-transporter 1-mediated glucose absorption in the small intestine

被引:13
|
作者
Chan, Leo K. Y. [1 ]
Wang, Yi [1 ]
Ng, Enders K. W. [2 ]
Leung, Po Sing [1 ]
机构
[1] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Room 609A, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Fac Med, Shatin, Hong Kong, Peoples R China
来源
DIABETES OBESITY & METABOLISM | 2018年 / 20卷 / 03期
关键词
diabetes; glucose intolerance; NHE3; inhibitor; postprandial hyperglycaemia; HYPOGLYCEMIC AGENT; TRANSPORTER SGLT1; RECEPTOR; ENTEROCYTES; ACTIVATION; KINASE; GROWTH; NHE3;
D O I
10.1111/dom.13151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimTo elucidate the role of Na+/H+ exchanger 3 (NHE3) in sodium-glucose co-transporter 1 (SGLT1)-mediated small intestinal brush border membrane (BBM) glucose absorption and its functional implications in type 2 diabetes mellitus (T2DM). Materials and MethodsHuman jejunal samples were obtained from patients undergoing gastrectomy. C-14-glucose absorption was measured by liquid scintillation counting. NHE3 expression was suppressed by siRNA-mediated knockdown or augmented in Caco2 cells. Glucose and insulin tolerance in db/db and m+/db mice was assessed with oral and intraperitoneal glucose tolerance tests, and an intraperitoneal insulin tolerance test. Insulin resistance and -cell function were assessed using homeostatic model assessment of insulin resistance and -cell function. ResultsNHE3 expression was upregulated in db/db mouse jejunal BBM and high-glucose-treated Caco2 cells. NHE3 blockade impaired SGLT1-mediated glucose absorption in human jejunum, m+/db and db/db mouse jejunums, and Caco2 cells, via serum/glucocorticoid-regulated kinase 1 (SGK1). NHE3 knockdown suppressed SGLT1-mediated glucose uptake and reduced mRNA and protein levels of SGK1 and SGLT1, which were conversely enhanced by NHE3 overexpression. Chronic S3226 treatment diminished postprandial glucose levels and ameliorated glucose intolerance in db/db mice. ConclusionNHE3 is essential in the modulation of small intestinal BBM glucose absorption. Our findings provide a rationale for future possible clinical application of NHE3 for treatment of T2DM through reducing intestinal glucose uptake and counteracting postprandial hyperglycaemia.
引用
收藏
页码:709 / 717
页数:9
相关论文
共 50 条
  • [31] Sodium glucose co-transporter 2 inhibitors: A novel approach to the management of type 2 diabetes mellitus
    Davis, Courtney S.
    Fleming, Joshua W.
    Warrington, Laurie E.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2014, 26 (07) : 356 - 363
  • [32] A CASE SERIES OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR USE IN TYPE 1 DIABETES IN A RURAL SETTING
    Drake, Stephanie
    May, Stephen
    INTERNAL MEDICINE JOURNAL, 2024, 54 : 23 - 23
  • [33] Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
    Lamos, Elizabeth M.
    Younk, Lisa M.
    Davis, Stephen N.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (06) : 875 - 882
  • [34] Effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, on diuresis and neurohormonal activation in type 2 diabetes mellitus and heart failure
    Takeuchi, T.
    Dohi, K.
    Omori, T.
    Moriwaki, K.
    Sugiura, E.
    Kumagai, N.
    Fujimoto, N.
    Fujii, E.
    Yamada, N.
    Itou, M.
    EUROPEAN HEART JOURNAL, 2016, 37 : 620 - 620
  • [35] Patient Characteristics of Sodium-Glucose Co-transporter 2 Inhibitors Initiators with Type 2 Diabetes Mellitus: A US Claims Database Analysis
    Yu, Shengsheng
    Fan, Chun-Po Steve
    Li, Zhiyi
    Hanna, Becky
    Tang, Jackson
    Williams, Jean
    DIABETES, 2015, 64 : A334 - A334
  • [36] Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes
    Lam, Karen S. L.
    Chow, Chun Chung
    Tan, Kathryn C. B.
    Ma, Ronald C. W.
    Kong, Alice P. S.
    Tong, Peter C. Y.
    Tsang, Man Wo
    Chan, Tak Mao
    Tang, Sydney C. W.
    Lee, Ka Kui
    So, Wing Yee
    Tomlinson, Brian
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (06) : 1097 - 1108
  • [37] Considerations for Initiating a Sodium-Glucose Co-Transporter 2 Inhibitor in Adults With Type 2 Diabetes Using Insulin
    Woo, Vincent C.
    Berard, Lori D.
    Bajaj, Harpreet S.
    Ekoe, Jean-Marie
    Senior, Peter A.
    CANADIAN JOURNAL OF DIABETES, 2018, 42 (01) : 88 - 93
  • [38] Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes
    Kushner, Pamela
    WOMENS HEALTH, 2016, 12 (03) : 379 - 388
  • [39] Dietary lipid modulation of Na+/glucose co-transporter (SGLT1), Na+/K+ ATPase, and ornithine decarboxylase gene expression in the rat small intestine in diabetes mellitus
    Wild, GE
    Turner, R
    Chao, LGS
    Faria, J
    Keelan, M
    Clandinin, MT
    Thomson, ABR
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 1997, 8 (12): : 673 - 680
  • [40] Effects of sodium-glucose co-transporter 2 inhibition on renal functions following an acute coronary syndrome in patients with type 2 diabetes
    Bacaksiz, Ahmet
    Sisman, Behice Hande
    Uzunoglan, Sezgin
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2022, 26 : S4 - S6